Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Almac | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Almac

Revenues up 8% in 2013

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac reported revenues were up 8% to £325 million in 2013, and pre-tax profits were £19.2 million, up 30%.
 
Alan Armstrong, chief executive officer of Almac, said, “2013 was an exciting year for us with a major jobs boost in Craigavon as we completed a non-GMP drug development facility and expanded our manufacturing capabilities, announced a £13 million investment in cancer research projects with Queen’s University and signed a $9 million deal with Genomic Health, securing the rights to further develop and commercialize our breast cancer test.
 
“We have continued to invest in R&D and capital programs and this year is set to be another successful one both at our headquarters in Craigavon and globally, following the opening of our new offices in Asia, and looking ahead to the launch of our new facility in Singapore early next year,” added Mr. Armstrong.
 
Almac provides a range of integrated services to companies globally within the pharma and biopharma sectors.The company employs approximately 3,400 people globally, with 2,000 based at its Craigavon Headquarters. The company has a U.S. operation in PA and recently opened regional hubs in Singapore and Japan expanding its services in the Asian market.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics